Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. Duijkers (Zaandam, Netherlands). Cytokine-based prediction of aetiology in community acquired pneumonia. 4110

Member's Comments

No comment yet.

Related content which might interest you: Using roncoleukine in basic therapy of patients with community acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 443s Year: 2002 Severe community acquired pneumonia: clinical and aetiological evaluation Source: Eur Respir J 2007; 30: Suppl. 51, 673s Year: 2007 The usage of thiotriazolin in complex treatment of patients with community acquired pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 579s Year: 2005 Etiologic evaluation of community acquired pneumonia Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Validation of a computer predictive model to stratify risk and site of care in community acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Etiology and prognosis factors in severe community acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 477s Year: 2002 The influence of CRB-65 and some clinical and epidemiological factors over approach to community acquired pneumonia Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia Source: Eur Respir J 2001; 18: 362-368 Year: 2001 Factors related to obtain an etiological diagnosis in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia Year: 2007 Diagnosis and management of community acquired pneumonia in adults Source: Virtual Congress 2020 – Clinical grand round: revisiting current guidelines Year: 2020 Evaluation of clinical efficiency of thiotriazolin in complex treatment of patients with community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006 Defining stability in pneumonia and the non-responding pneumonia Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Healthcare-associated pneumonia among hospitalized patients. Is it really different from community acquired pneumonia? Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Improving outcome in elderly patients with pneumonia Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI Year: 2005 Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Factors associated with unknown aetiology in patients with community-acquired pneumonia Source: Eur Respir J 2002; 20: 1254-1262 Year: 2002 Comparison of pneumonia severity scoring methods in identification of severe community acquired pneumonia Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017 Clinical presentation and evolution of community acquired pneumonia in older patients Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Management of community acquired pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010